405 related articles for article (PubMed ID: 32372943)
21. A Human Neural Crest Stem Cell-Derived Dopaminergic Neuronal Model Recapitulates Biochemical Abnormalities in GBA1 Mutation Carriers.
Yang SY; Beavan M; Chau KY; Taanman JW; Schapira AHV
Stem Cell Reports; 2017 Mar; 8(3):728-742. PubMed ID: 28216145
[TBL] [Abstract][Full Text] [Related]
22. The emerging role of autophagic-lysosomal dysfunction in Gaucher disease and Parkinson's disease.
Kinghorn KJ; Asghari AM; Castillo-Quan JI
Neural Regen Res; 2017 Mar; 12(3):380-384. PubMed ID: 28469644
[TBL] [Abstract][Full Text] [Related]
23. Increased glucosylsphingosine levels and Gaucher disease in GBA1-associated Parkinson's disease.
Marano M; Zizzo C; Malaguti MC; Bacchin R; Cavallieri F; De Micco R; Spagnolo F; Bentivoglio AR; Schirinzi T; Bovenzi R; Ramat S; Erro R; Sorrentino C; Sucapane P; Pilotto A; Lupini A; Magliozzi A; Di Vico I; Carecchio M; Bonato G; Cilia R; Colucci F; Tamma F; Caputo E; Mostile G; Arabia G; Modugno N; Zibetti M; Ceravolo MG; Tambasco N; Cossu G; Valzania F; Manganotti P; Di Lazzaro V; Zappia M; Fabbrini G; Tinazzi M; Tessitore A; Duro G; Di Fonzo A
Parkinsonism Relat Disord; 2024 Jun; 124():107023. PubMed ID: 38843618
[TBL] [Abstract][Full Text] [Related]
24. Ambroxol reverses tau and α-synuclein accumulation in a cholinergic N370S GBA1 mutation model.
Yang SY; Taanman JW; Gegg M; Schapira AHV
Hum Mol Genet; 2022 Jul; 31(14):2396-2405. PubMed ID: 35179198
[TBL] [Abstract][Full Text] [Related]
25. A double-hit in vivo model of GBA viral microRNA-mediated downregulation and human alpha-synuclein overexpression demonstrates nigrostriatal degeneration.
Polissidis A; Koronaiou E; Nikolopoulou G; Viel C; Nikatou M; Bogiongko M; Sardi SP; Xilouri M; Vekrellis K; Stefanis L
Neurobiol Dis; 2022 Feb; 163():105612. PubMed ID: 34995756
[TBL] [Abstract][Full Text] [Related]
26. Loss of glucocerebrosidase 1 activity causes lysosomal dysfunction and α-synuclein aggregation.
Bae EJ; Yang NY; Lee C; Lee HJ; Kim S; Sardi SP; Lee SJ
Exp Mol Med; 2015 Mar; 47(3):e153. PubMed ID: 25813221
[TBL] [Abstract][Full Text] [Related]
27. Live cell
Labrador-Garrido A; Zhong S; Hughes L; Keshiya S; Kim WS; Halliday GM; Dzamko N
Front Cell Neurosci; 2023; 17():1229213. PubMed ID: 37908374
[TBL] [Abstract][Full Text] [Related]
28. The GBA1 D409V mutation exacerbates synuclein pathology to differing extents in two alpha-synuclein models.
Polinski NK; Martinez TN; Ramboz S; Sasner M; Herberth M; Switzer R; Ahmad SO; Pelligrino LJ; Clark SW; Marcus JN; Smith SM; Dave KD; Frasier MA
Dis Model Mech; 2022 Jun; 15(6):. PubMed ID: 35419585
[TBL] [Abstract][Full Text] [Related]
29. The Molecular Impact of Glucosylceramidase Beta 1 (Gba1) in Parkinson's Disease: a New Genetic State of the Art.
Dos Santos JCC; Mano GBC; da Cunha Barreto-Vianna AR; Garcia TFM; de Vasconcelos AV; Sá CSG; de Souza Santana SL; Farias AGP; Seimaru B; Lima MPP; Goes JVC; Gusmão CTP; Junior HLR
Mol Neurobiol; 2024 Feb; ():. PubMed ID: 38347286
[TBL] [Abstract][Full Text] [Related]
30. Acid ceramidase inhibition ameliorates α-synuclein accumulation upon loss of GBA1 function.
Kim MJ; Jeon S; Burbulla LF; Krainc D
Hum Mol Genet; 2018 Jun; 27(11):1972-1988. PubMed ID: 29579237
[TBL] [Abstract][Full Text] [Related]
31. Genome-wide association study of glucocerebrosidase activity modifiers.
Somerville EN; Krohn L; Senkevich K; Yu E; Ahmad J; Asayesh F; Ruskey JA; Speigelman D; Fahn S; Waters C; Sardi SP; Alcalay RN; Gan-Or Z
Res Sq; 2024 Jun; ():. PubMed ID: 38883744
[TBL] [Abstract][Full Text] [Related]
32. Mutant GBA1 expression and synucleinopathy risk: first insights from cellular and mouse models.
Sardi SP; Singh P; Cheng SH; Shihabuddin LS; Schlossmacher MG
Neurodegener Dis; 2012; 10(1-4):195-202. PubMed ID: 22327140
[TBL] [Abstract][Full Text] [Related]
33. Glucocerebrosidase expression patterns in the non-human primate brain.
Dopeso-Reyes IG; Sucunza D; Rico AJ; Pignataro D; Marín-Ramos D; Roda E; Rodríguez-Pérez AI; Labandeira-García JL; Lanciego JL
Brain Struct Funct; 2018 Jan; 223(1):343-355. PubMed ID: 28835999
[TBL] [Abstract][Full Text] [Related]
34. Molecular mechanisms of α-synuclein and GBA1 in Parkinson's disease.
Stojkovska I; Krainc D; Mazzulli JR
Cell Tissue Res; 2018 Jul; 373(1):51-60. PubMed ID: 29064079
[TBL] [Abstract][Full Text] [Related]
35. Inhibition of cysteine protease cathepsin L increases the level and activity of lysosomal glucocerebrosidase.
Kim MJ; Kim S; Reinheckel T; Krainc D
JCI Insight; 2024 Feb; 9(3):. PubMed ID: 38329128
[TBL] [Abstract][Full Text] [Related]
36. Gaucher-related synucleinopathies: the examination of sporadic neurodegeneration from a rare (disease) angle.
Sardi SP; Cheng SH; Shihabuddin LS
Prog Neurobiol; 2015 Feb; 125():47-62. PubMed ID: 25573151
[TBL] [Abstract][Full Text] [Related]
37. N370S-GBA1 mutation causes lysosomal cholesterol accumulation in Parkinson's disease.
García-Sanz P; Orgaz L; Bueno-Gil G; Espadas I; Rodríguez-Traver E; Kulisevsky J; Gutierrez A; Dávila JC; González-Polo RA; Fuentes JM; Mir P; Vicario C; Moratalla R
Mov Disord; 2017 Oct; 32(10):1409-1422. PubMed ID: 28779532
[TBL] [Abstract][Full Text] [Related]
38. DNA Methylation of α-Synuclein Intron 1 Is Significantly Decreased in the Frontal Cortex of Parkinson's Individuals with
Smith AR; Richards DM; Lunnon K; Schapira AHV; Migdalska-Richards A
Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36769009
[TBL] [Abstract][Full Text] [Related]
39. The role of glucocerebrosidase in Parkinson disease pathogenesis.
Gegg ME; Schapira AHV
FEBS J; 2018 Oct; 285(19):3591-3603. PubMed ID: 29385658
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
